Europe and the Middle East

Valeant has expanded its presence throughout Europe and the Middle East, generating revenues in more than 20 countries – primarily in Poland, Russia, France and Germany – from pharmaceutical products, branded generics, OTC products and medical devices.  

Valeant’s strategy in Central and Eastern Europe is to develop and commercialize generics and OTC products that represent a quality, affordable alternative to brand counterparts. Branded generic products are sold largely under the Valeant umbrella brand. However, in countries where the brand names of legacy companies still resonate with healthcare professionals and consumers, Valeant has chosen (for certain products) to retain on its packaging the logos of some of the historical companies that also make up Valeant Europe.

Valeant Europe, Middle East and North Africa (EMENA) produces medicines – pharmaceutical products, branded generics, OTC products and medical devices – that meet the special health problems of patients in more than 35 countries.

Within Central and Eastern Europe, Valeant develops and commercializes generics and OTC products that represent a quality, affordable alternative to brand counterparts. Branded generic products are sold largely under the Valeant umbrella brand. However, in countries where the brand names of legacy companies still resonate with healthcare professionals and consumers, Valeant retains (for certain products) on its packaging the logos of some of the historical companies that make up Valeant Europe. 

The combined branded generics business covers a number of treatments including antibiotics, treatments for cardiovascular and neurological diseases, dermatological products and diabetic therapies.

Valeant dramatically expanded its footprint in the region with the 2015 acquisition of Amoun Pharmaceutical, the largest domestic company in the Egyptian pharmaceutical market. Amoun operates a large, state-of-the-art manufacturing plant that is considered to be one of the largest and most up-to-date pharmaceutical facilities in Africa and the Middle East, and has market-leading pharmaceutical brands in such therapeutic areas as anti-hypertensives, broad-spectrum antibiotics and anti-diarrheals.         

Learn more about Valeant EMENA at its website.